Senior Manager

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

ESSENTIAL JOB FUNCTIONS:

Reporting to the Executive Director, Scientific Communications & Publications, you will be responsible for supporting strategic planning and driving tactical execution of publication deliverables for assigned programs. As an integral team member in Medical Affairs, you will collaborate closely with cross-functional teams to manage and execute strategic publication plans and leverage your expertise to support preparation for our first commercial launch.

• Lead development and manage the execution of publication tactics (eg, manuscripts, abstracts, posters, oral presentations) for assigned programs in accordance with company policies and procedures
• Lead routine publication team meetings to facilitate strategic discussions/decisions related to publication planning and execution
• Serve as Publications Lead for assigned programs and represent Sci Comms & Publications on cross-functional teams
• Contribute to the development of an annual Strategic Publication Plan with an understanding of how these activities support the overall Medical Affairs strategy and corporate goals
• Closely collaborate with teams to draft and develop abstracts, posters, oral presentations, manuscripts, slide decks, and other content for medical/scientific audiences
• Poise to facilitate alignment among various internal and external stakeholders (eg, authors, cross-functional teams, researchers, journal editors)
• Critically review/edit complex publication documents for quality, compliance, and scientific integrity
• Support publication standardization to ensure consistent and compliant practices across the company
• Manage development of a scientific platform for assigned programs as needed
• Establish strong and effective working relationships with key stakeholders internally (product teams, clinical, medical) and externally (authors, KOLs)
• Directly manage publication vendor(s) and budgets, where required

JOB SPECIFICATIONS:

• Advanced scientific degree (PharmD or PhD preferred)
• 4+ years of direct publications experience in the pharmaceutical or biotech industry
• Oncology and/or Hematology experience is highly preferred
• Excellent verbal and written communication skills; strong project management skills
• Ability to prioritize projects and thrive in a dynamic, fast-paced environment
• Understanding of industry regulations and guidelines governing publications and medical communications (eg, GPP, ICMJE, Sunshine Act/PhRMA Code of Conduct)
• Experience managing vendors and a budget is preferred
• Certified Medical Publication Professional (CMPP) preferred

The base range for a Senior Manager is $179,000 - $201,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.